Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Recurrent Hepatocellular Carcinoma

  • End date
    Aug 9, 2023
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 12 September 2021


The purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced recurrent hepatocellular carcinoma.

Condition Recurrent Hepatocellular Carcinoma
Treatment Sintilimab and Bevacizumab Combined with Radiotherapy
Clinical Study IdentifierNCT05010434
SponsorSun Yat-sen University
Last Modified on12 September 2021


Yes No Not Sure

Inclusion Criteria

Age: 18-75 years
ECOG (Eastern Cooperative Oncology Group) 0-1
Locally advanced or advanced recurrent hepatocellular carcinoma (HCC) that cannot be surgically removed
Have not received anti-tumor system therapy
At least 1 measurable lesion (according to RECIST 1.1)
Child-Pugh Class A
At least 12 weeks of life expectancy
Adequate hematologic, hepatic and renal function: Hb 90g/L, ANC(absolute neutrophil count) 1.5x10^9/L, PLT(platelet count) 60 x10^9/L, ALT(alanine aminotransferase) and AST(aspartate aminotransferase) 3ULN(upper limit of normal), total bilirubin 1.5ULN, serum creatinine 1.5ULN, albumin 30g/L
Contraception during the study
Willing to join the study and sign informed consent

Exclusion Criteria

HCV (hepatitis C virus) infection
History of allergy to anti-PD-1 (PD-1, programmed cell death protein 1) monoclonal antibody and anti-VEGF (VEGF, vascular endothelial growth factor) monoclonal antibody
Have other malignant tumors within 5 years, except for fully treated skin basal cell cancer and cervical cancer
Poor blood pressure control. In the case of taking medication, systolic blood pressure>140mmHg or diastolic blood pressure>90mmHg
Received radiotherapy for liver disease
History of hepatic encephalopathy
Received transplantation
Severe pleural effusion, ascites or pericardial effusion
History of autoimmune diseases and autoimmune deficiency
Receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days before the first administration
Active infections that require systemic treatment, such as active tuberculosis
History of idiopathic pulmonary fibrosis, tissue pneumonia, drug-induced pneumonia or idiopathic pneumonia, or active pneumonia found in chest CT examination
Severe bleeding
Esophageal and gastric varices with high risk of bleeding and not fully treated; rupture of esophageal and gastric varices occurred within 6 months before the first administration
Required daily treatment with non-steroidal anti-inflammatory drugs (NSAID)
Accompanying diseases that seriously endanger the safety of the patient or affect the completion of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note